C.M. Woodroffe - Concepedia

Author

C.M. Woodroffe

Queen Elizabeth Hospital Birmingham

Also Known As

C M Woodroffe, C Woodroffe, C. M. Woodroffe, C.M. Woodroffe, CHARLOTTE M. WOODROFFE, CM Woodroffe, Charlotte Woodroffe

Publications

920

Citations

H-Index

Concepts

All Affiliations

Queen Elizabeth Hospital Birmingham Queen Elizabeth Hospital Nottingham City Hospital

About

C.M. Woodroffe is an author at Queen Elizabeth Hospital Birmingham specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	413
2	Pathology	4	4	233
3	Health Sciences	3	3	54
4	Pharmacology	3	3	167
5	Surgical Oncology	1	1	29

C.M. Woodroffe

Publications

910

Citations

H-Index

Page 1

	Year	Citations
Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life M.H. Cullen, Lucinda Billingham, C.M. Woodroffe, Journal of Clinical Oncology	1999	448
Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare M.H. Cullen, RameshC. Joshi, A.D. Chetiyawardana, British Journal of Cancer MedicinePharmacologyPathologyBronchial NeoplasmAnti-cancer Agent	1988	124
Long-term toxicity of chemotherapy for testicular cancer – the cost of cure NSA Stuart, C.M. Woodroffe, Richard G. Grundy, British Journal of Cancer UrologyTesticular CancerMedicineCancer ManagementLong-term Toxicity	1990	97
Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: A randomised, controlled trial Michael Cullen, D.A.L. Morgan, Walter M. Gregory, Cancer Chemotherapy and Pharmacology MedicinePathologyMaintenance ChemotherapyBronchial NeoplasmCancer Treatment	1986	67
Quality of life after treatment for testicular cancer—the patient's view N Stuart, Richard G. Grundy, C.M. Woodroffe, European Journal of Cancer and Clinical Oncology Quality Of LifeUrologySurgical OncologyTesticular Cancer—the PatientMedicine	1990	29
Testing new drugs in untreated small cell lung cancer may prejudice the results of standard treatment: a phase II study of oral idarubicin in extensive disease. M.H. Cullen, Sandra R. Smith, G. F. A. Benfield, PubMed OncologyExtensive ScclMetronomic TherapyPharmacologyClinical Trials	1987	29
26 Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): 3. Results of a randomised trial evaluating palliation & quality of life Lucinda Billingham, M.H. Cullen, Jack Woods, Lung Cancer MedicineRandomised TrialCancer ManagementPathologyCancer Treatment	1997	26
Chemotherapy for Poor Risk Germ Cell Tumours An Independent Evaluation of the POM B/ACE Regime M.H. Cullen, Peter Harper, C.M. Woodroffe, British Journal of Urology	1988	26
ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group. M.H. Cullen, N Stuart, C.M. Woodroffe, Journal of Clinical Oncology	1994	23
11 Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): 2. Results of a randomised trial in patients with extensive disease M.H. Cullen, C.M. Woodroffe, Lucinda Billingham, Lung Cancer MedicineRandomised TrialMetronomic TherapyPathologyExtensive Disease	1997	16

Page 1